RT Journal Article
T1 Pharmacokinetic and Pharmacodynamic Modeling of Enrofloxacin and Its Metabolite Ciprofloxacin in Pregnant Goats.
A1 Ambros, Luis Adrian
A1 Kreil, Verónica
A1 Lucas Burneo, José Julio De
A1 Tinti, Mariano Guillermo
A1 San Andrés Larrea, Manuel Ignacio
A1 Lorenzutti, Augusto Matías
AB The pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin, as well as the placental transfer of enrofloxacin and ciprofloxacin, have not been studied. The aims of this study were (1) to evaluate the pharmacokinetics of enrofloxacin and ciprofloxacin by intravenous and intramuscular administration of 7.5 mg/kg in pregnant goats; (2) to determine the placental transfer of enrofloxacin and ciprofloxacin; (3) to conduct a PK/PD analysis to calculate the PK/PD cutoff of different dose regimens; and (4) to evaluate the tentative epidemiological cutoff values for coagulase-negative staphylococci wild-type isolates from goats. Plasmatic concentrations of enrofloxacin and ciprofloxacin in pregnant goats were well described by the parent-metabolite model. Simultaneous modeling of enrofloxacin and ciprofloxacin in each individual allowed for a PK/PD analysis that considered both drugs with antimicrobial activity. Our results show that both enrofloxacin and ciprofloxacin crossed the placenta in goats: fetal/maternal concentration ratio were 0.58 ± 0.05 and 0.03 ± 0.01 for enrofloxacin and ciprofloxacin. MIC values of coagulase-negative staphylococci isolates ( = 90) were obtained, and tentative epidemiological cutoffs were calculated at 0.25 and 0.5 mg/L for enrofloxacin and ciprofloxacin. According to PK/PDco values, an intravenous dose regimen of 10 mg/kg/day was considered the most appropriate, but based on the PK/PDco, culture, and AST data, an effective dosing regimen with the lowest possible dose could be selected to minimize the potential risk of fetal exposure to enrofloxacin.
PB MDPI
YR 2025
FD 2025
LK https://hdl.handle.net/20.500.14352/122764
UL https://hdl.handle.net/20.500.14352/122764
LA eng
NO Ambros, L. A., Kreil, V., de Lucas Burneo, J. J., Tinti, M. G., San Andrés Larrea, M. I., & Lorenzutti, A. M. (2025). Pharmacokinetic and Pharmacodynamic Modeling of Enrofloxacin and Its Metabolite Ciprofloxacin in Pregnant Goats. Veterinary Sciences, 12(6), 588. https://doi.org/10.3390/vetsci12060588
NO Justificación de autores:L.A.A.: methodology, validation, investigation, resources, writing—review and editing, visualization, project administration, funding acquisition. V.K.: conceptualization, methodology, validation, investigation, resources, data curation, writing—review and editing. J.J.d.L.B.: conceptualization, methodology, validation, investigation, writing—review and editing. M.G.T.: methodology, software, formal analysis, data curation. M.I.S.A.L.: project administration, conceptualization, methodology, writing—review and editing, visualization, supervision. A.M.L.: conceptualization, methodology, software, formal analysis, investigation, data curation, writing—original draft preparation, writing—review and editing, visualization. All authors have read and agreed to the published version of the manuscript
NO Universidad de Buenos Aires
DS Docta Complutense
RD 18 dic 2025